---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-037760"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:05:52.772243+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BrainStorm reports FY2025 net loss $10.3M; secures $2M post-year-end for Phase 3b

## Summary
- Cash, equivalents, restricted cash $0.3M at Dec 31, 2025; raised $2M in Feb 2026 private placements.
- Net loss $10.3M ($1.11/share) vs $11.6M ($2.31/share) in 2024; R&D spend $4.2M, G&A $5.8M.
- FDA cleared Phase 3b ENDURANCE study of NurOwn for ALS; ~200 participants, SPA and CMC aligned.
- Expanded Access Program: 5/10 patients alive, mean survival ~84 months; all 10 exceeded 5-year survival.
- Company highlights $2M strategic financing as catalyst for share re-rating and cash runway for operations.

## SEC filing metadata
- accession: 0001104659-26-037760
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465926037760/0001104659-26-037760-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465926037760/tm2610751d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-037760
- JSON: https://secwatch.observer/filing/0001104659-26-037760.json
- Plain text: https://secwatch.observer/filing/0001104659-26-037760.txt

## Source-grounded claims
- claim_id: de3fc235106aa4addf2bd202643c02580c9d1a0b
  claim: BRAINSTORM CELL THERAPEUTICS INC. reported the full year ended December 31, 2025 results: net income Net loss for the twelve months ended December 31, 2025, was approximately $10.3 million, EPS Net loss per share for the twelve months ended December 31, 2025, and 2024 was $1.11 and $2.31, respectively.
  evidence_excerpt: On March 31, 2026, Brainstorm Cell Therapeutics Inc. issued a press release announcing its financial results for the year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1137883/000110465926037760/0001104659-26-037760-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.